Financhill
Sell
37

RNAC Quote, Financials, Valuation and Earnings

Last price:
$9.56
Seasonality move :
9.13%
Day range:
$9.36 - $10.02
52-week range:
$8.46 - $41.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.36x
P/B ratio:
568.21x
Volume:
42K
Avg. volume:
72.8K
1-year change:
-69.59%
Market cap:
$248.1M
Revenue:
$38.9M
EPS (TTM):
-$1.15

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RNAC
Cartesian Therapeutics
$771.4K -$0.55 -97.69% -98.63% $36.17
AMGN
Amgen
$8.9B $5.38 5.67% 279.07% $314.20
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.43 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RNAC
Cartesian Therapeutics
$9.56 $36.17 $248.1M -- $0.00 0% 6.36x
AMGN
Amgen
$288.18 $314.20 $155B 26.29x $2.38 3.21% 4.57x
NBY
NovaBay Pharmaceuticals
$0.55 $0.85 $3.2M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.52 -- $24.4M -- $0.00 0% --
OGEN
Oragenics
$0.12 $1.00 $2.6M -- $0.00 0% 1.15x
TOVX
Theriva Biologics
$0.47 $7.00 $3.8M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RNAC
Cartesian Therapeutics
-- 2.846 -- 12.15x
AMGN
Amgen
90.24% 0.239 34.26% 0.74x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RNAC
Cartesian Therapeutics
-- -$21.9M -- -- -1989.91% -$24.2M
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Cartesian Therapeutics vs. Competitors

  • Which has Higher Returns RNAC or AMGN?

    Amgen has a net margin of -1610% compared to Cartesian Therapeutics's net margin of 21.23%. Cartesian Therapeutics's return on equity of -- beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    RNAC
    Cartesian Therapeutics
    -- -$0.68 -$21.8M
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About RNAC or AMGN?

    Cartesian Therapeutics has a consensus price target of $36.17, signalling upside risk potential of 278.31%. On the other hand Amgen has an analysts' consensus of $314.20 which suggests that it could grow by 9.03%. Given that Cartesian Therapeutics has higher upside potential than Amgen, analysts believe Cartesian Therapeutics is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RNAC
    Cartesian Therapeutics
    4 2 0
    AMGN
    Amgen
    10 14 2
  • Is RNAC or AMGN More Risky?

    Cartesian Therapeutics has a beta of 0.634, which suggesting that the stock is 36.568% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

  • Which is a Better Dividend Stock RNAC or AMGN?

    Cartesian Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.21% to investors and pays a quarterly dividend of $2.38 per share. Cartesian Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios RNAC or AMGN?

    Cartesian Therapeutics quarterly revenues are $1.1M, which are smaller than Amgen quarterly revenues of $8.1B. Cartesian Therapeutics's net income of -$17.7M is lower than Amgen's net income of $1.7B. Notably, Cartesian Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 26.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics is 6.36x versus 4.57x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RNAC
    Cartesian Therapeutics
    6.36x -- $1.1M -$17.7M
    AMGN
    Amgen
    4.57x 26.29x $8.1B $1.7B
  • Which has Higher Returns RNAC or NBY?

    NovaBay Pharmaceuticals has a net margin of -1610% compared to Cartesian Therapeutics's net margin of -49.65%. Cartesian Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    RNAC
    Cartesian Therapeutics
    -- -$0.68 -$21.8M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About RNAC or NBY?

    Cartesian Therapeutics has a consensus price target of $36.17, signalling upside risk potential of 278.31%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 54.55%. Given that Cartesian Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cartesian Therapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RNAC
    Cartesian Therapeutics
    4 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is RNAC or NBY More Risky?

    Cartesian Therapeutics has a beta of 0.634, which suggesting that the stock is 36.568% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock RNAC or NBY?

    Cartesian Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RNAC or NBY?

    Cartesian Therapeutics quarterly revenues are $1.1M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cartesian Therapeutics's net income of -$17.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Cartesian Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics is 6.36x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RNAC
    Cartesian Therapeutics
    6.36x -- $1.1M -$17.7M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns RNAC or NNVC?

    Nanoviricides has a net margin of -1610% compared to Cartesian Therapeutics's net margin of --. Cartesian Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RNAC
    Cartesian Therapeutics
    -- -$0.68 -$21.8M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About RNAC or NNVC?

    Cartesian Therapeutics has a consensus price target of $36.17, signalling upside risk potential of 278.31%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 327.63%. Given that Nanoviricides has higher upside potential than Cartesian Therapeutics, analysts believe Nanoviricides is more attractive than Cartesian Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    RNAC
    Cartesian Therapeutics
    4 2 0
    NNVC
    Nanoviricides
    0 0 0
  • Is RNAC or NNVC More Risky?

    Cartesian Therapeutics has a beta of 0.634, which suggesting that the stock is 36.568% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock RNAC or NNVC?

    Cartesian Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RNAC or NNVC?

    Cartesian Therapeutics quarterly revenues are $1.1M, which are larger than Nanoviricides quarterly revenues of --. Cartesian Therapeutics's net income of -$17.7M is lower than Nanoviricides's net income of -$2.2M. Notably, Cartesian Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics is 6.36x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RNAC
    Cartesian Therapeutics
    6.36x -- $1.1M -$17.7M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns RNAC or OGEN?

    Oragenics has a net margin of -1610% compared to Cartesian Therapeutics's net margin of --. Cartesian Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RNAC
    Cartesian Therapeutics
    -- -$0.68 -$21.8M
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About RNAC or OGEN?

    Cartesian Therapeutics has a consensus price target of $36.17, signalling upside risk potential of 278.31%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 733.33%. Given that Oragenics has higher upside potential than Cartesian Therapeutics, analysts believe Oragenics is more attractive than Cartesian Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    RNAC
    Cartesian Therapeutics
    4 2 0
    OGEN
    Oragenics
    0 1 0
  • Is RNAC or OGEN More Risky?

    Cartesian Therapeutics has a beta of 0.634, which suggesting that the stock is 36.568% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock RNAC or OGEN?

    Cartesian Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RNAC or OGEN?

    Cartesian Therapeutics quarterly revenues are $1.1M, which are larger than Oragenics quarterly revenues of --. Cartesian Therapeutics's net income of -$17.7M is lower than Oragenics's net income of -$2.2M. Notably, Cartesian Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics is 6.36x versus 1.15x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RNAC
    Cartesian Therapeutics
    6.36x -- $1.1M -$17.7M
    OGEN
    Oragenics
    1.15x -- -- -$2.2M
  • Which has Higher Returns RNAC or TOVX?

    Theriva Biologics has a net margin of -1610% compared to Cartesian Therapeutics's net margin of --. Cartesian Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RNAC
    Cartesian Therapeutics
    -- -$0.68 -$21.8M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About RNAC or TOVX?

    Cartesian Therapeutics has a consensus price target of $36.17, signalling upside risk potential of 278.31%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1399.25%. Given that Theriva Biologics has higher upside potential than Cartesian Therapeutics, analysts believe Theriva Biologics is more attractive than Cartesian Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    RNAC
    Cartesian Therapeutics
    4 2 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is RNAC or TOVX More Risky?

    Cartesian Therapeutics has a beta of 0.634, which suggesting that the stock is 36.568% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock RNAC or TOVX?

    Cartesian Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RNAC or TOVX?

    Cartesian Therapeutics quarterly revenues are $1.1M, which are larger than Theriva Biologics quarterly revenues of --. Cartesian Therapeutics's net income of -$17.7M is lower than Theriva Biologics's net income of -$4.3M. Notably, Cartesian Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics is 6.36x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RNAC
    Cartesian Therapeutics
    6.36x -- $1.1M -$17.7M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Best AI Index Fund to Buy
Best AI Index Fund to Buy

Over the last two years, companies with a focus on…

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

2 Ultra Safe Dividend Stocks to Buy Now
2 Ultra Safe Dividend Stocks to Buy Now

Historically, blue-chip dividend stocks have been good choices for periods…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
31
REGN alert for May 31

Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Sell
42
AMBA alert for May 31

Ambarella [AMBA] is down 15.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock